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Aim To evaluate whether history of pregnancy complications [pre-eclampsia, gestational hypertension, preterm delivery,
or small for gestational age (SGA)] improves risk prediction for cardiovascular disease (CVD).
...................................................................................................................................................................................................
Methods
and results
This population-based, prospective cohort study linked data from the HUNT Study, Medical Birth Registry of
Norway, validated hospital records, and Norwegian Cause of Death Registry. Using an established CVD risk predic-
tion model (NORRISK 2), we predicted 10-year risk of CVD (non-fatal myocardial infarction, fatal coronary heart
disease, and non-fatal or fatal stroke) based on established risk factors (age, systolic blood pressure, total and
HDL-cholesterol, smoking, anti-hypertensives, and family history of myocardial infarction). We evaluated whether
adding pregnancy complication history improved model fit, calibration, discrimination, and reclassification. Among
18 231 women who were parous, >_40 years of age, and CVD-free at start of follow-up, 39% had any pregnancy
complication history and 5% experienced a CVD event during a median follow-up of 8.2 years. While pre-
eclampsia and SGA were associated with CVD in unadjusted models (HR 1.96, 95% CI 1.44–2.65 for pre-eclampsia
and HR 1.46, 95% CI 1.18–1.81 for SGA), only pre-eclampsia remained associated with CVD after adjusting for
established risk factors (HR 1.60, 95% CI 1.16–2.17). Adding pregnancy complication history to the established pre-
diction model led to small improvements in discrimination (C-index difference 0.004, 95% CI 0.002–0.006) and re-
classification (net reclassification improvement 0.02, 95% CI 0.002–0.05).
...................................................................................................................................................................................................
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Conclusion Pre-eclampsia independently predicted CVD after controlling for established risk factors; however, adding pre-
eclampsia, gestational hypertension, preterm delivery, and SGA made only small improvements to CVD prediction
among this representative sample of parous Norwegian women.
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Introduction
Cardiovascular disease (CVD) is the leading cause of death in
women1 and is underdiagnosed in women compared to men.2,3
Cardiovascular disease risk prediction tools are commonly used to
identify individuals at higher risk, allowing physicians to target inter-
ventions to patients who would benefit the most. However, clinical
guidelines have noted that current tools identify few high risk women
prior to age 70 and have called for research to improve sensitivity for
younger women.4,5
Pregnancy may provide an ideal ‘window’ to predict future cardio-
vascular health in young women.6,7 Emerging evidence suggests that
pregnancy complications, including pre-eclampsia,8,9 gestational
hypertension,10 preterm delivery,11,12 and delivery of an infant small
for gestational age (SGA),13–15 are associated with future CVD.
Associations between pregnancy complications and CVD are likely
due to shared etiologic pathways7 (e.g. metabolic syndrome, vascular
dysfunction, and inflammation). Current guidelines recommend
screening women for pregnancy complications and monitoring car-
diovascular risk factors postpartum.2,16,17 However, it is unclear
whether pregnancy complications also have utility in predicting CVD
above-and-beyond established risk factors already included in predic-
tion models. There is some evidence that pregnancy complications
do not lead to large improvements in CVD risk prediction.18,19
However, only one previous study examined the benefit of adding
pregnancy complications to existing CVD prediction models in a clin-
ical setting,18 and no published studies have examined the benefit of
adding history of preterm delivery or SGA to existing models.
Using linked data from the Nord-Trøndelag Health Study (the
HUNT Study), the Medical Birth Registry of Norway (MBRN), vali-
dated hospital records, and the Norwegian Cause of Death Registry,
we evaluated whether adding history of pregnancy complications to
the NORRISK 2 risk prediction model,20 the model currently recom-
mended for use in clinical practice in Norway,21 improved prediction
performance in parous women.
Methods
Study population
The HUNT Study is an ongoing population-based cohort study of resi-
dents in Norway’s Nord-Trøndelag county. Approximately every decade,
all county residents 20 years of age and older are invited to participate in
an extensive health assessment, including a clinical examination and ques-
tionnaires.22 Three surveys were completed by the time of this analysis,
HUNT1 (1984–86),23 HUNT2 (1995–97),24 and HUNT3 (2006–08).22
Using the national identification number assigned to Norwegian citizens,
we linked HUNT data to the MBRN25 to capture information about all
deliveries that occurred after the birth registry began in 1967.
We restricted this analysis to participants in the HUNT2 and HUNT3
surveys, during which serum samples were collected for all participants,
to enable inclusion of lipids in CVD risk prediction models. We identified
a total of 27 862 parous women who participated in HUNT2 and/or
HUNT3 and had a birth registered in the MBRN (Figure 1). As the
NORRISK 2 CVD risk prediction model20 included only adults ages
40 years and older, we excluded women younger than 40 years at the
time of the HUNT exam (n= 9056). We also excluded women with a his-
tory of CVD prior to the HUNT exam (n= 292). History of CVD was
identified through either (i) self-report of myocardial infarction (MI) or
stroke via questionnaire during the HUNT exam or any previous HUNT
exam (including HUNT1) or (ii) validated record of hospitalization for MI
or stroke from the start of record collection in 1987 through the date of
the HUNT exam. After additionally excluding women with incomplete
data on covariates used in the NORRISK 2 prediction model20 (n= 283),
the final study population included 18 231 women. All HUNT study par-
ticipants signed an informed consent form permitting use of their data
and samples for research. The Central Norway Regional Committee for
Medical and Health Research Ethics approved this project, and the
Harvard T. H. Chan School of Public Health exempted this project from
IRB review.
Established cardiovascular risk factors
Established risk factors [including systolic blood pressure, total choles-
terol, high density lipoprotein cholesterol (HDL-C), smoking, anti-
hypertensive use, and family history of premature MI] were chosen to
match the NORRISK 220 model to the extent possible. Trained HUNT
study staff measured systolic blood pressure and collected non-fasting
serum samples to quantify total cholesterol and HDL-C. We defined low
HDL-C as <1.3 mmol/L. Supplementary material online, Table S1 includes
additional measurement details. From the HUNT questionnaires, we
identified current daily smoking and current anti-hypertensive use at the
time of the HUNT exam as well as family history of premature MI,
defined as having a first-degree family member who suffered a MI before
the age of 60 years.
Pregnancy complications
We identified pregnancy complication history from the MBRN, including
all pregnancies from 1967 to the time of the HUNT exam. Diagnoses of
pre-eclampsia or gestational hypertension used internationally recom-
mended criteria,26,27 with gestational hypertension generally defined as
de novo hypertension (>_140 mmHg systolic and/or >_90 mmHg diastolic)
after 20 weeks of gestation, and pre-eclampsia also requiring proteinuria
(300 mg/24 h or >_1þ on the dipstick test). We identified gestation length
based on ultrasound dating where available (2% of deliveries) or last men-
strual period and defined preterm delivery as <37 weeks gestation.
Multiple gestational pregnancies delivered <37 weeks were excluded
from the preterm delivery definition. Small for gestational age was defined
as the lowest 10% of birthweights by gestational age and sex observed in
2 A.R. Markovitz et al.
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..the MBRN,28 with percentiles calculated separately for multiple vs. single
gestational pregnancies. Validation studies within HUNT26,29 found posi-
tive predictive values (PPV) of 88% for pre-eclampsia and 93% for pre-
term delivery. Gestational hypertension’s PPV was 68%, due in part to
mislabeling of pre-eclampsia cases as gestational hypertension. Among
women classified as gestational hypertensives, 88% had a hypertensive
disorder of pregnancy (HDP). Although SGA was not included in valid-
ation studies, the PPV for low birth weight (<2500 g) in the HUNT study
was 100%. Pregnancy complications were analysed using separate varia-
bles indicating whether the women had a history of the complication of
interest across any pregnancy.
Cardiovascular endpoints
Consistent with NORRISK 2, we predicted hard CVD endpoints (non-
fatal MI, fatal CHD, or non-fatal or fatal stroke). CVD events were cap-
tured from the two primary hospitals in Nord-Trøndelag county:
Levanger Hospital and Namsos Hospital (Nord-Trøndelag Hospital
Trust) from 1, September 1987 (the beginning of electronic recording)
through 24 April 2015. All study participants with at least one cardiovas-
cular diagnosis had their medical records reviewed by one of the two
experienced cardiologists (B.K. and H.D.) to determine the first validated
occurrence of MI or stroke. We diagnosed MI using Joint ESC/ACCF/
AHA/WHF Task Force criteria30 and stroke based on typical symptoms
and signs combined with radiological evidence from CT or MRI scans.
Supplementary material online, Text S1 includes additional validation pro-
cess details. In addition, we identified fatal CVD events using ICD diagnos-
tic codes from the national Cause of Death Registry, which has
had mandatory reporting since 1951 (Supplementary material online,
Table S2).
Statistical analysis
We sought to compare an established CVD risk factor model to that
same model additionally including history of pregnancy complications.
For each of these models, we used the same statistical methods as
NORRISK 2.20 We estimated the 10-year risk of CVD using Fine and
Gray competing risk models,31 accounting for deaths from other causes
as competing events. Women contributed person-time to the analysis
from the index HUNT exam through first CVD event, death from other
causes, or censoring at either the end of data collection on 24 April 2015
or emigration from Nord-Trøndelag county. Women who participated
in both the HUNT2 and HUNT3 exams (n= 8313) were allowed to con-
tribute two independent (non-overlapping) observations to the analysis
as long as they met eligibility criteria at the start of follow-up. These
women could contribute an observation with follow-up (i.e. at the time
of the exam) from HUNT2 to HUNT3 using risk factor information
assessed at the time of HUNT2 and an observation with follow-up from
Participated in HUNT2 and/or HUNT3 and 
had a birth registered in the MBRN
Women = 27,862
Observations = 43,492                                          
Total included in analysis
Women = 18,231
Observations = 26,544                              
Participated in HUNT2
Women = 22,390                             
Participated in HUNT3
Women = 21,102                            
Included in analysis from HUNT2
Women = 11,916                             
Included in analysis from HUNT3
Women = 14,628                             
Excluded:
- 10,212 age <40 years at 
HUNT exam
- 168 CVD event prior to 
HUNT exama
- 94 incomplete data on 
covariates used in 
NORRISK 2
Excluded:
- 5,278 age <40 years at 
HUNT exam
- 546 CVD event prior to 
HUNT exama
- 950 incomplete data on 
covariates used in 
NORRISK 2
Figure 1 Flow chart of study population. aIncludes self-reported history of myocardial infarction or stroke at HUNT exam and hospitalizations for
myocardial infarction or stroke recorded from 1987 through the date of HUNT exam. CVD, cardiovascular disease; HUNT, the Nord-Trøndelag
Health Study; MBRN, Medical Birth Registry of Norway.
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HUNT3 using risk factor information assessed during HUNT3. Although
women could have contributed more than 10 years of follow-up to the
analysis based on the timing of exams, we predicted CVD risk at 10 years
of follow-up. To account for the correlation in measurements among
women who participated in HUNT2 and HUNT3, we used variance esti-
mates which account for repeated measures32 (Supplementary material
online, Text S2). Some pregnancies were missing from the registry due to
women giving birth before the start of the birth registry in 1967 (n= 4387
women), and some pregnancies had missing values for gestation length
and/or birthweight or pregnancies with Z-scores for birthweight by ges-
tation length that were >4 or <-4, suggesting error during data entry
(n= 2042 women). We used multiple imputation to impute pregnancy
complications for these pregnancies missing from the registry or with in-
complete information in the registry. Supplementary material online, Text
S2 provides details about multiple imputation methods used.
We calculated measures of model fit, calibration, discrimination, and
reclassification because no single measure captures all of the information
needed to assess improvement in model performance after adding preg-
nancy complications.33 Prior to building models, we compared the estab-
lished risk factors between those with and without a history of pregnancy
complications and tested whether there were significant differences using
either v2 tests for categorical measures or Student’s t-tests for continu-
ous measures. We then estimated an unadjusted model including only
pregnancy complications to confirm their ability to predict CVD end-
points in our population. Next, we identified whether the addition of
pregnancy complications to the established risk factor model improved
model fit using a Wald test. We assessed model calibration (the equiva-
lence between observed CVD risk and model-predicted CVD risk) for
models using the Greenwood–Nam–D’Agostino test for censored sur-
vival data.34 We measured model discrimination (the ability to distinguish
between CVD cases and non-cases) by obtaining the C-index for each
model and comparing the difference between them.35 The C-index is an
extension of the concept of the area under the receiver operating charac-
teristic (ROC) curve but modified to be appropriate for the survival
setting.
A key indicator of improved model performance is if, after adding
pregnancy complications, women who went on to have a CVD
event were reclassified into higher risk categories while women who
did not have an event were reclassified into lower risk categories.36
This information is summarized in the net reclassification improve-
ment (NRI) which we calculated overall and separately among women
who did and did not go on to have a CVD event, using an extension
of the formula for survival data.37 To calculate these measures, we
stratified women into clinically relevant categories based on their 10-
year risk of CVD: low (<5%), intermediate (5 to <10%), and high
(>_10%). We also calculated the integrated discrimination improve-
ment (IDI),36 which is a related measure of model improvement that
does not rely on cut-points to categorize risk. Confidence intervals
for discrimination and reclassification measures were calculated using
1000 bootstraps. All analyses were performed using SAS version 9.4
(SAS Institute Inc., Cary, NC, USA) and used publically available mac-
ros to assess prediction performance.38 See Supplementary material
online, Text S2 for additional details about prediction performance
measures.
Additional analyses
In post hoc analyses suggested by reviewers, we included additional
terms for recurrent pregnancy complications (i.e. for each pregnancy
complication, having experienced the complication during two or
more pregnancies) and interaction terms between the pregnancy
complications to test alternative parameterizations for modelling
pregnancy complication history. As a sensitivity analysis, we also
tested the degree of model overfitting to our dataset by adjusted esti-
mates of discrimination and reclassification for model optimism using
1000 bootstrap samples.39
Results
Among 18 231 parous women, 965 (5%) had an incident CVD event
during follow-up (median 8.2 years, interquartile range 7.4–11.1 years)
while 295 (2%) died from other causes. Non-fatal events comprised
the majority of incident CVD events (97%) with 5% dying on the day of
or within 30 days of the event. Thirty percent of women experienced
at least one pregnancy complication based on birth registry records.
After imputing pregnancy complications for births not captured in the
registry, 39% of women had a history of pregnancy complications in
any pregnancy. In age-standardized comparisons, women with a history
of pregnancy complications based on birth registry records had higher
systolic blood pressure (P< 0.001) and were more likely to smoke
(P< 0.001), take anti-hypertensives (P< 0.001), have low HDL
(P= 0.006), and have a family history of premature MI (P< 0.001) com-
pared to women with no pregnancy complications (Table 1).
Model fit
The associations between established risk factors and CVD were
similar to those reported in the original NORRISK 2 publication by
Selmer et al.20 (Supplementary material online, Table S3). In unadjust-
ed models including all pregnancy complications, pre-eclampsia, and
SGA were independently associated with CVD (HR 1.96, 95% CI
1.44–2.65 for pre-eclampsia and HR 1.46, 95% CI 1.18–1.81 for SGA)
(Table 2). After adjusting for the established risk factors only pre-
eclampsia was associated with an increased rate of CVD (HR 1.60,
95% CI 1.16–2.17). Model fit was improved with the addition of preg-
nancy complications (Wald test P= 0.04).
Calibration
The established risk factor model was well-calibrated both before
(P= 0.23 for the null hypothesis of equal observed and predicted
risk) and after (P= 0.26) the addition of pregnancy complications.
A visual depiction of model calibration is provided in Supplementary
material online, Figure S1.
Discrimination
Inclusion of pregnancy complications in the established risk factor
model led to a statistically significant but small 0.004 increase in the
C-index (95% CI 0.002–0.006) (Take home figure). This small im-
provement in discrimination was driven mostly by the inclusion of
pre-eclampsia (Table 3).
Reclassification of clinical risk categories
Among the 965 women with an incident CVD event during
follow-up, 38 were correctly reclassified into a higher risk cat-
egory after the inclusion of pregnancy complication history while
17 were incorrectly reclassified into a lower risk category
(Table 4). This lead to a marginal improvement in reclassification
as measured by the NRI for events (0.02, 95% CI -0.002 to 0.04).
Among the 25579 observations without a CVD event, 274 were
4 A.R. Markovitz et al.
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incorrectly reclassified into a higher risk category while 375 were
correctly reclassified into a lower risk category, which similarly
resulted in a small improvement in reclassification [NRI for non-
events 0.004 (95% CI 0.002–0.006)]. Overall, there was a small
improvement in reclassification 0.02 (95% CI 0.002–0.05). No
obvious improvements in reclassification were apparent when
examining continuous predicted probabilities (Supplementary
material online, Figure S2) and the IDI [-0.0002 (95% CI -0.001 to
0.0007)] did not indicate overall improvement on a continuous
scale. Similar small improvements in reclassification were
observed when comparing the established risk factor model to a
model including pre-eclampsia history only (Supplementary ma-
terial online, Table S4) and no improvement in reclassification
was seen for the other pregnancy complications examined
individually.
Additional analyses
Including additional variables for recurrent pregnancy complications
and interactions between pregnancy complications did not lead to
substantial improvements in prediction performance compared to
models including only a single variable for history of each pregnancy
complication (Supplementary material online, Table S5). Estimates
were similar after adjusting for optimism (Supplementary material
online, Table S6).
Discussion
Addition of pregnancy complication history led to very modest to no
improvements in an established cardiovascular risk prediction model
recommended for clinical practice in Norway. We observed
improvements in model discrimination and reclassification; however,
differences were small in magnitude and unlikely to be clinically
meaningful. Although pre-eclampsia and SGA were significant predic-
tors of atherosclerotic CVD events in unadjusted models, only pre-
eclampsia predicted an increased risk of CVD after adjusting for
established risk factors.
Comparison with current literature
Previous studies have examined the association between pregnancy com-
plications and CVD8–15; however, significant associations do not neces-
sarily translate into improved prediction.40 Only one previous study
based on clinical data assessed prediction model performance after add-
ing pregnancy complications and similarly found very modest to no im-
provement in CVD risk prediction.18 Our study expands on this work
using a larger general population sample, covering a wider age range,
using validated CVD events, and including preterm and SGA history in
addition to hypertensive disorders of pregnancy. Our findings are also
supported by a recent study based on self-reported data in female nurses,
in which previous pre-eclampsia did not improve CVD risk prediction.19
....................................................................................................................................................................................................................
Table 1 Descriptive statistics of parous HUNT2 and HUNT3 participants by history of pregnancy complications at
start of follow-up
All study participants
(n5 26 544a)
Did not experience
a pregnancy
complicationb(n5 18 608a)
Experienced at
least one pregnancy
complicationb(n5 7936a)
Age at HUNT exam in years, median (IQR) 52 (46–59) 52 (46–60) 51 (46–58)
Age-standardizedc risk factors from NORRISK 2 model
Systolic blood pressure in mmHg, median (IQR) 128 (117–142) 127 (116–141) 130 (118–144)
Serum total cholesterol in mmol/L, median (IQR) 5.8 (5.1–6.6) 5.8 (5.1–6.6) 5.8 (5.1–6.6)
Current daily smoking 31% 29% 35%
Current anti-hypertensive use 13% 12% 18%
Low HDL-Cd 37% 37% 39%
Family history of premature MIe 17% 16% 19%
Reproductive history
Number of births
1 8% 8% 7%
2 38% 39% 37%
3 34% 34% 35%
4þ 19% 19% 21%
Pre-eclampsia in any pregnancy 5% 0% 17%
Gestational hypertension in any pregnancy 4% 0% 12%
Any preterm delivery 8% 0% 28%
Any small for gestational age delivery 18% 0% 62%
HUNT, the Nord-Trøndelag Health Study; HDL-C, high density lipoprotein cholesterol; IQR, interquartile range; MI, myocardial infarction.
aWomen who participated in only HUNT2 (n= 3603) or HUNT3 (n= 6315) contributed one observation while women who participated in both HUNT2 and HUNT3
(n= 8313) contributed two.
bPregnancy complications include pre-eclampsia, gestational hypertension, preterm delivery, and small for gestational age delivery.
cRisk factors standardized to the age distribution of the study population.
dLow HDL-C <1.3 mmol/L.
eFirst degree family member suffered MI before the age of 60 years.
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The goal of this study was to examine the ability of pregnancy
complications to predict CVD rather than their associations; how-
ever, it is worth noting that the magnitude of observed associations
between pregnancy complications and CVD in our study were lower
than those reported in previous studies, particularly for preterm, ges-
tational hypertension, and SGA.10–15 This was true even compared
to some Norwegian studies,41–44 although one study found similarly
small estimates for preterm and SGA.44 Many previous studies were
conducted using death registries and associations with pregnancy
complications tend to be lower for non-fatal events8,11 which com-
prised the majority of events included in this study. Most previous
studies also began follow-up time immediately after an index birth
and there is some evidence that associations between pregnancy
complications and CVD are substantially stronger at younger
ages.45,46 In contrast, we started follow-up for CVD events after age
40 (mean = 52 years) to mimic clinical settings in which NORRISK 2
is used, which could also contribute to the modest associations seen
in our study. In addition, few previous studies have adjusted for estab-
lished risk factors included in prediction models.8,12 There is evidence
that the association between HDP and CVD is mediated to a sub-
stantial degree by CVD risk factors,47 which may explain why includ-
ing pre-eclampsia in the NORRISK 2 model did not substantially
improve discrimination or reclassification.
Prediction modelling choices
We chose the NORRISK 2 as our established risk factor model
because it is currently recommended for clinical practice in
Norway and was built using Norwegian data, including HUNT2
data among other sources. All decisions about how to model
variables were made a priori, aligning with NORRISK 2 wherever
possible, thus the risk of overfitting the prediction model to our
dataset was low. We also confirmed that estimates were similar
after adjusting for model optimism. We used identical definitions
...................................................... .................................... .....................................................
....................................................................................................................................................................................................................
Table 2 Hazard ratios for 10-year cardiovascular disease risk from Fine and Gray competing risk models comparing
models with and without pregnancy complication history
Covariates Unadjusted model for pregnancy
complication history
Established risk factor
model
Established risk factor model1
pregnancy complication historyd
HRc 95% CI HRc 95% CI HRc 95% CI
Age (per 1 year) 1.09 1.06–1.13 1.10 1.06–1.13
Age squared (per 1 year) 1.00 1.00–1.00 1.00 1.00–1.00
Systolic blood pressure (per 10 mmHg) 1.19 1.11–1.28 1.19 1.10–1.28
Serum total cholesterol (per 1 mmol/L) 1.12 1.06–1.18 1.12 1.06–1.18
Daily smoking (yes/no) 3.22 2.37–4.37 3.24 2.38–4.41
Systolic blood pressure  age 1.00 1.00–1.00 1.00 1.00–1.00
Daily smoking  age 0.98 0.97–1.00 0.98 0.97–1.00
Anti-hypertensives (yes/no) 1.41 1.21–1.66 1.38 1.16–1.64
Low HDL-cholesterol (yes/no)a 1.65 1.45–1.87 1.65 1.45–1.87
Family history of premature MIb 1.53 1.31–1.77 1.52 1.30–1.76
Pre-eclampsia in any pregnancy (yes/no) 1.96 1.44–2.65 1.60 1.16–2.17
Gestational HTN in any pregnancy (yes/no) 1.16 0.70–1.89 0.73 0.46–1.15
Any preterm delivery (yes/no) 1.13 0.85–1.51 0.98 0.73–1.31
Any SGA delivery (yes/no) 1.46 1.18–1.81 1.06 0.85–1.32
CI, confidence interval; HDL-C, high density lipoprotein cholesterol; HR, hazard ratio; HTN, hypertension; MI, myocardial infarction; SGA, small for gestational age.
aLow HDL-cholesterol: < 1.3 mmol/L.
bFirst degree family member suffered MI before the age of 60 years.
cCVD-specific hazard ratio from Fine and Gray competing risk model.
dWald test for joint significance of all four pregnancy complications: P= 0.04.
Take home ﬁgure Pregnancy complications did not substan-
tially improve 10-year cardiovascular disease risk prediction com-
pared with an established model.
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of model variables, CVD outcomes, and modelling techniques as
the NORRISK 2 model with only one exception. NORRISK 2
includes separate variables for one compared to two or more
family members with premature MI; however, this level of detail
was not collected in HUNT3 so we used a single variable to
summarize any family history of premature MI. The NORRISK 2
model is used exclusively in Norway and pregnancy complica-
tions may improve model fit more or less using other established
risk prediction models. However, there is substantial overlap in
the variables and methods used in NORRISK 2 compared to
other commonly used CVD prediction models such as European
SCORE,48 Framingham,49 or Pooled Cohort Risk Equations.4
Although there are many ways to model pregnancy complication
history, we chose a priori to include a single variable indicating history
of each pregnancy complication because it would be more feasible to
implement a similar model in the clinical setting and aid in the inter-
pretation of results. Still, models with alternative parameterizations
of pregnancy complications yielded similar results, indicating little
benefit to increasing model complexity.
Limitations
While our study location in Nord-Trøndelag county is fairly repre-
sentative of Norway,24 findings may not be generalizable to non-
Nordic populations. For example, although smoking rates seen in our
study were similar to the female Norwegian average during our study
period,50 smoking prevalence is greater in Norway than most higher-
income countries. Our study was also limited to parous women who
made up about 90% of the population of women during the time
period of this study.51 We would expect similar findings after includ-
ing nulliparous women, although small improvements may be seen
.....................................................................................................................................................
.................................. .................................................. .............................. ..................
....................................................................................................................................................................................................................
Table 4 Reclassification of cardiovascular disease risk category after including pregnancy complication historya,b
Established CVD risk factor model1 pregnancy complication history
Low risk (0 to <5%) Intermediate risk (5 to <10%) High risk (10%) Total
Established CVD risk factor model N % N % N % N %
Observations with incident CVD event
0 to <5% 386 97% 19 7% 0 0% 405 42%
5 to <10% 12 3% 257 91% 19 7% 288 30%
>_10% 0 0% 5 2% 267 93% 272 28%
Total 398 281 286 965
Observations with no incident CVD event
0 to <5% 19 853 99% 179 5% 0 0% 20 032 78%
5 to <10% 251 1% 3482 92% 95 6% 3828 15%
>_10% 0 0% 124 3% 1595 94% 1719 7%
Total 20 104 3785 1690 25 579
Net reclassification improvement (NRI) = 0.02 (95% CI 0.002 to 0.05), P= 0.04.
NRI for events = 0.02 (95% CI -0.002 to 0.04), P= 0.08.
NRI for non-events = 0.004 (95% CI 0.002 to 0.006), P< 0.001.
Integrated discrimination improvement (IDI) = -0.0002 (95% CI -0.001 to 0.0007), P= 0.65.
aShaded areas represent improvements in reclassification after the addition of pregnancy complication history.
bThis table includes observations with censoring prior to 10 years or follow-up longer than 10 years (median = 8.2 years of follow-up). Reclassification metrics explicitly take
into account follow-up time (see Supplementary material online, Text S2) and cannot be directly calculated using numbers in this table.
....................................................................................................................................................................................................................
Table 3 Discrimination statistics comparing models with and without pregnancy complication history
Model C-index C-index difference
from established CVD
risk factor model
95% CI for C-index
difference
Established CVD risk factors 0.789
Established CVD risk factors þ pre-eclampsia in any pregnancy 0.792 0.003 (0.001–0.005)
Established CVD risk factors þ gestational HTN in any pregnancy 0.790 0.0006 (-0.0004 to 0.001)
Established CVD risk factors þ any preterm delivery 0.789 0.0002 (0.0001–0.0002)
Established CVD risk factors þ any SGA delivery 0.790 0.0003 (-0.0001 to 0.0008)
Established CVD risk factors þ all pregnancy complications 0.793 0.004 (0.002–0.006)
CI, confidence interval; CVD, cardiovascular disease; HTN, hypertension; SGA, small-for-gestational age.
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due to the association between parity and CVD.52,53 Another limita-
tion of this study was the lack of data on gestational diabetes, which
was likely underdiagnosed in the MBRN before 1988.54 The propor-
tion of women who had ever experienced a pregnancy complication
in this population (an estimated 39%) was higher than estimates from
the United States (29%)6 but similar to a study from the United
Kingdom (36%)55 One explanation for our high proportion of
women with pregnancy complication history in this study is the rela-
tively high fertility rate in Norway compared to other high-income
countries.56 Another explanation is that the reference population
used to identify birthweight percentiles by gestation length used a
more recent sample of births in the MBRN. An advantage of using an
external reference population is that our definition of SGA could be
more easily recreated in other populations; however, increases in
birthweights over time may have led to an overestimation of SGA
deliveries.
Strengths
Strengths of our study include the use of a general population sample
of parous women and assessment of CVD risk factors during exams
that reflect a realistic clinical scenario. In addition, 97% of the events
used in this study were validated by study staff. Our linkage project
provided a unique combination of rich clinical data, reproductive his-
tory, and follow-up for non-fatal and fatal events ideal for examining
this research question.
Clinical relevance and future directions
After adding pregnancy complications to the model, an additional
0.4% of women without events were correctly reclassified into
lower risk categories while 2% of women with events were cor-
rectly reclassified into higher risk categories. In Norway, risk
thresholds to initiative treatment to prevent CVD are age-specific
but roughly align with thresholds used in this article,21 thus we
would expect to see small improvements in appropriate treat-
ment if pregnancy complications to CVD risk prediction models in
clinical practice. While these benefits are small in magnitude, sub-
sequent studies should evaluate whether greater improvements
are seen for other populations, especially among younger women.
Pregnancy complications occur early in life and may be useful for
primary and primordial prevention in younger populations.
Findings should also be validated in other populations, including
non-Nordic countries.
Conclusion
In this population-based, prospective cohort study, pregnancy com-
plications (pre-eclampsia, gestational hypertension, preterm delivery,
and SGA) led to only small improvements in 10-year CVD risk pre-
diction for parous women, as measured by changes in model discrim-
ination and reclassification. Although overall prevalence of at least
one pregnancy complication was high in this population, pregnancy
complications were not strong enough independent predictors of
CVD after controlling for established risk factors to substantially im-
prove prediction performance.
Supplementary material
Supplementary material is available at European Heart Journal online.
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